Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 15.3% in April

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 9,400 shares, a decrease of 15.3% from the March 31st total of 11,100 shares. Based on an average daily trading volume, of 31,300 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are short sold.

Sol-Gel Technologies Stock Down 18.7 %

Shares of NASDAQ:SLGL traded down $0.16 during midday trading on Tuesday, hitting $0.71. The stock had a trading volume of 42,837 shares, compared to its average volume of 28,539. The company’s 50-day moving average price is $1.00 and its 200-day moving average price is $1.18. The company has a market capitalization of $19.85 million, a P/E ratio of -0.77 and a beta of 1.33. Sol-Gel Technologies has a fifty-two week low of $0.71 and a fifty-two week high of $4.05.

Sol-Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sol-Gel Technologies had a negative return on equity of 61.52% and a negative net margin of 1,331.01%. The company had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.27 million. Research analysts expect that Sol-Gel Technologies will post -0.67 EPS for the current fiscal year.

Institutional Trading of Sol-Gel Technologies

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Yelin Lapidot Holdings Management Ltd. purchased a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 229,178 shares of the company’s stock, valued at approximately $374,000. Yelin Lapidot Holdings Management Ltd. owned 0.99% of Sol-Gel Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 26.18% of the company’s stock.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.